- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: relapsed multiple myeloma
Total 17204 results
-
Washington University School of MedicineBristol-Myers Squibb; CelgeneActive, not recruitingMultiple Myeloma in RelapseUnited States, Canada
-
OHSU Knight Cancer InstituteSanofi; Oregon Health and Science UniversityActive, not recruitingRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
GlaxoSmithKlineTerminatedMultiple MyelomaUnited States
-
European Myeloma NetworkFondazione EMN Italy OnlusCompleted
-
GlaxoSmithKlineActive, not recruitingMultiple MyelomaAustralia, Japan, Spain, Germany, Poland, Belgium, Israel, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, China, Brazil, Czechia, United States, Netherlands, United Kingdom, Greece, France
-
Hackensack Meridian HealthActive, not recruitingMultiple MyelomaUnited States
-
Duke UniversityGlaxoSmithKlineCompletedMultiple MyelomaUnited States
-
Janssen-Cilag Ltd.Legend BiotechCompletedMultiple MyelomaBelgium, United States, United Kingdom, Italy, Germany, Netherlands, Spain, France, Russian Federation, Poland
-
TakedaCompletedRelapsed/Refractory Multiple MyelomaJapan
-
TakedaCompletedRelapsed and/or Refractory Multiple MyelomaJapan
-
Bristol-Myers SquibbActive, not recruiting
-
Memorial Sloan Kettering Cancer CenterActive, not recruiting
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.; Celgene CorporationActive, not recruitingMultiple Myeloma in RelapseUnited States
-
Beth Israel Deaconess Medical CenterGenzyme, a Sanofi CompanyCompletedAcute Myeloid Leukemia | Myelodysplastic Syndrome | Acute Lymphocytic Leukemia | Hodgkins Disease | Relapsed/Refractory Chronic Lymphocytic Leukemia | Relapsed Refractory Multiple Myeloma | Relapsed/Refractory Non Hodgkin's LymphomaUnited States
-
Cancer Trials IrelandBristol-Myers Squibb; Janssen PharmaceuticalsActive, not recruiting
-
CelgeneActive, not recruitingMultiple MyelomaAustria
-
TeneoOne Inc.AbbVieActive, not recruitingMultiple MyelomaUnited States, Germany
-
University of VirginiaWithdrawnMultiple MyelomaUnited States
-
LaNova Medicines LimitedWithdrawnRelapsed or Refractory Multiple Myeloma | Other Plasma Cell Diseases
-
SanofiCompletedPlasma Cell MyelomaFrance, Spain, Greece, Korea, Republic of, United States, Australia, Belgium, Canada, Czechia, Denmark, Germany, Hungary, Italy, Japan, New Zealand, Norway, Poland, Portugal, Russian Federation, Slovakia, Sweden, Taiwan, Turkey, United...
-
GlaxoSmithKlineActive, not recruiting
-
CelgeneActive, not recruitingMultiple MyelomaUnited States, Spain
-
OncotherapeuticsCelgene CorporationTerminatedMultiple MyelomaUnited States
-
OncotherapeuticsAmgenTerminatedMultiple MyelomaUnited States
-
OncotherapeuticsTakedaCompletedMultiple MyelomaUnited States
-
Weill Medical College of Cornell UniversityKaryopharm Therapeutics IncTerminatedRefractory Multiple Myeloma | Myeloma | Myeloma MultipleUnited States
-
Memorial Sloan Kettering Cancer CenterWeill Medical College of Cornell University; Celgene Corporation; University... and other collaboratorsCompletedMultiple Myeloma | Non-Hodgkin's LymphomaUnited States
-
Kite, A Gilead CompanyTerminatedRelapsed/Refractory Multiple MyelomaUnited States
-
AbbVieCompletedMultiple Myeloma (MM)United States, Argentina, Australia, Brazil, Canada, Croatia, Czechia, France, Germany, Greece, Ireland, Israel, Italy, Netherlands, Norway, Poland, Romania, Saudi Arabia, Slovenia, Spain, Taiwan, Turkey
-
BeBetter Med IncCompletedRelapsed or Refractory Multiple Myeloma | Relapsed or Refractory Non-Hodgkin's LymphomaChina
-
AmgenTerminatedRelapsed/Refractory Multiple MyelomaUnited States, Australia, Japan, Germany, Netherlands, Canada
-
GWT-TUD GmbHActive, not recruitingRefractory Multiple MyelomaGermany
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); City of Hope Medical Center and other collaboratorsCompletedRecurrent Plasma Cell MyelomaUnited States
-
CelgeneActive, not recruitingMultiple MyelomaUnited States, Canada, Denmark, Australia, Belgium, Finland, Greece, Japan, Korea, Republic of, Spain, United Kingdom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Non-Secretory Plasma Cell Myeloma | PlasmacytosisUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingIdasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaRecurrent Plasma Cell Myeloma | Loss of Chromosome 17pUnited States
-
Srinivas DevarakondaTerminatedRecurrent Plasma Cell MyelomaUnited States
-
National Cancer Institute (NCI)WithdrawnRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
Raija SilvennoinenBristol-Myers Squibb; Amgen; Hospital District of Helsinki and UusimaaCompletedMultiple Myeloma in RelapseFinland, Sweden
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
HitGen Inc.TerminatedMultiple Myeloma | Relapsed and Refractory Multiple MyelomaChina
-
Cellectis S.A.TerminatedRelapsed/Refractory Multiple MyelomaUnited States
-
Mundipharma Research LimitedActive, not recruitingMultiple Myeloma | Hodgkin's Lymphoma | Hematological Malignancies | Cutaneous T Cell LymphomaFrance, United States, Netherlands, Spain, Switzerland, Germany, Italy
-
SanofiTerminatedPlasma Cell MyelomaTaiwan, United States, Czechia, France, Greece, Spain
-
Precision BioSciences, Inc.TerminatedRelapsed/Refractory Multiple MyelomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Juno Therapeutics, Inc.CompletedRefractory Plasma Cell Myeloma | Recurrent Plasma Cell MyelomaUnited States
-
University of NebraskaM.D. Anderson Cancer CenterTerminatedCabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaMultiple Myeloma | Refractory Multiple Myeloma | Relapsed/Refractory Multiple MyelomaUnited States
-
SanofiCompleted